IMRN News and Press, Immuron Limited From 04/11/25

2025-04-11 03:35:14 ET More on Immuron Seeking Alpha’s Quant Rating on Immuron Historical earnings data for Immuron Financial information for Immuron Read the full article on Seeking Alpha For further details see: Immuron exceeds AUD$5 mill...

Sales Highlights (unaudited): MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan ® , an over...

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand....

Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates...

Highlights: Travelan ® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan ® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results Travelan ® (IMM-124E) Phase 2 Clinical Study Statistically Signific...